一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Apatinib；CDK4/6 Inhibitor；Aromatase inhibitor and Fulvestrant，当前状态为研究进行中，已停止招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Apatinib；CDK4/6 Inhibitor；Aromatase inhibitor and Fulvestrant · III 期
登记条件中文摘要
登记的基本范围为女性，年龄18 岁至75 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
公开的入选条件
- * Inclusion Criteria:
- * Patients need to meet all of the following conditions
- Patients must be ≥18 and ≤ 75 years of age;
- Pathologically confirmed breast cancer is HR+/HER2- breast cancer (IHC ER \>10%, or/and PR\>10%, HER 0 OR +, if HER2++, FISH negative);
- SNF4 subtype definition: SNF4 subtype confirmed by digital pathology of H\&E sections;
- Locally advanced breast cancer (radical local therapy is not possible) or metastatic breast cancer (without using adjuvant CDK4/6 inhibitors in the past, or one year after adjuvant CDK4/6 inhibitor therapy has ended);
- No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer;
- Patients with at least one measurable lesion that has not previously received radiation therapy and can be evaluated repeatedly according to RECIST 1.1;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06447623；登记信息更新于 2026-09-25。